Physician profile
Jeffrey C-J Liu
NPI 1679732796
$2,740.30
in general payments reported to CMS, 2019-2025
19 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 84% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $55.49 · 2023: $241 · 2024: $1,145 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.81 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $995.90 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Genzyme Corporation | $370.99 | 2024-2025 | |
| Janssen Biotech, INC. | $221.22 | 2023 | Tremfya, Stelara |
| Glaxosmithkline, LLC. | $204.31 | 2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $195.44 | 2024 | |
| Medtronic, INC. | $175.00 | 2025 | Propel |
| Boston Scientific Corporation | $174.31 | 2025 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $140.26 | 2024-2025 | Dupixent, Libtayo |
| Isoray, INC | $55.49 | 2020 | |
| Novus Surgical Consultants | $34.77 | 2025 | |
| Ucb, INC. | $24.47 | 2025 | |
| Paratek Pharmaceuticals, INC. | $24.00 | 2025 | Xhance |
| Cvrx, INC. | $19.92 | 2023 | Barostim Neo System |
| Sun Pharmaceutical Industries INC. | $19.63 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.10 | 2025 | Tezspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.39 | 2025 | Tezspire |
| Axsome Therapeutics, INC. | $18.21 | 2025 | Sunosi |
| Cipher Pharmaceuticals US LLC | $15.01 | 2025 | Natroba, Spinosad |
| Pfizer INC. | $13.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.